Enhancing circulating adiponectin is considered as a potential approach for the prevention and treatment of non-communicable diseases (NCDs). Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were reported to increase adiponectin by previous studies using a mixture of them. However, their individual effects on adiponectin and the underlying mechanisms are still unclear. In the present study, we observed and compared the individual effect of DHA and EPA on adiponectin in 3T3-L1 adipocytes, and further tested whether DHA or EPA regulated adiponectin by peroxisome proliferator-activated receptor γ (PPARγ) and its phosphorylation at Ser273 to provide a plausible explanation for their distinct actions. Firstly, 3T3-L1 adipocytes were treated with different doses of DHA or EPA for 24 h. Secondly, 3T3-L1 adipocytes were treated with DHA or EPA in the presence or absence of GW9662. Thirdly, 3T3-L1 adipocytes were pretreated with DHA or EPA for 24 h, followed by being respectively co-incubated with tumor necrosis factor α (TNF-α) or roscovitine for another 2 h. Bovine serum albumin treatment served as the control. After treatments, cellular and secreted adiponectin, cellular PPARγ and its phosphorylation at Ser273 were determined. Compared with the control, DHA increased cellular and secreted adiponectin at 50 and 100 μmol/L, while EPA increased them at 100 and 200 μmol/L. Adiponectin expressions in DHA treated groups were significantly higher than those in EPA treated groups at 50 and 100 μmol/L. Both DHA and EPA enhanced PPARγ expression, but DHA was more effective. GW9662 blocked DHA- and EPA-induced increases in PPARγ as well as adiponectin. Remarkably, an opposite regulation of PPARγ phosphorylation was detected after fatty acids treatment: DHA inhibited it but EPA stimulated it. TNF-α blocked DHA-induced decrease in PPARγ phosphorylation, which eventually led to a decrease in adiponectin. Roscovitine blocked EPA-induced increase in PPARγ phosphorylation, but the corresponding increase in adiponectin was non-significant. DHA compared with EPA led to a greater increase in cellular and secreted adiponectin at relative low concentrations by increasing PPARγ expression and inhibiting its phosphorylation at Ser273. DHA may be more beneficial than EPA in reducing risks of NCDs.
Inhibiting β‐amyloid (Aβ) aggregation is of significance in finding potential candidates for Alzheimer's disease (AD) treatment. Accumulating evidence suggests that nutrition is important for improving cognition and reducing AD risk. Walnut has been widely used as a functional food for brain health; however the underlying mechanisms remain unknown. Here, we investigated the molecular level alteration in Arctic mutant Aβ42 induced aggregation cell model by RNA‐seq and iTRAQ approaches after walnut‐derived peptides Pro‐Pro‐Lys‐Asn‐Trp (PW5) and Trp‐Pro‐Pro‐Lys‐Asn (WN5) interventions. PW5 or WN5 could significantly decrease abnormal Aβ42 aggregates. However, resultant alterations in transcriptome (substantially unchanged) were inconsistent with proteomic data (marked change). Proteomic analysis revealed 184 and 194 differentially expressed proteins unique to PW5 and WN5 treatment, respectively, for inhibiting Aβ42 protein production or increasing protein degradation via the mismatch repair pathways. Our study provides new insights into the effectiveness of food‐derived peptides for anti‐Aβ42 aggregation in AD.